Clinical Trial Update: A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study [Phase 2]

View source ↗

Summary

This clinical trial update notes that the Phase 2 study of ASP8273 for subjects with non-small cell lung cancer with EGFR activating mutations has been withdraw…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ASP8273

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Subjects With NSCLC With an EGFR Activating Mutation | Phase 2 | Status: WITHDRAWN